Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $55.0, with a high ...
Carlsbad’s Ionis strikes deal with Japanese pharma worth up to $940M
Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine ...
Fierce Pharma3d
Ionis, Arrowhead, Amarin sponsor new triglyceride group to educate physicians
Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. | Ionis ...
Pharmaceutical Technology on MSN4d
Ionis and Sobi agree on olezarsen commercialisation
As the European commercialisation partner of Ionis for Waylivra (volanesorsen), Sobi is set to utilise its current market ...
Ionis Pharmaceuticals (NASDAQ:IONS) Upgraded to Sell at StockNews.com
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) was upgraded by analysts at StockNews.com to a “sell” rating in a ...
Natixis Advisors LLC Sells 6,767 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Natixis Advisors LLC lowered its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 32.1% during ...
Explore more
Ionis Pharmaceuticals enters exclusive olezarsen license agreement with Sobi
Ionis Pharmaceuticals (IONS) announced that it has entered into a license agreement under which Sobi received exclusive rights in countries ...
Ionis Pharmaceuticals price target lowered to $45 from $47 at JPMorgan
JPMorgan lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $45 from $47 and keeps a Neutral rating on the shares. The firm ...
National Triglyceride Alliance Launches to Advance Clinician Education on High Triglycerides and the Importance of Proactive Triglyceride Management
The National Triglyceride Alliance (NTA) is proud to announce its official launch, marking a pivotal step in advancing ...
Seeking Alpha5d
IONS Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with ...
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement under which Sobi® ...
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.